Global Oncology Academy

Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
Project Oncology®
Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
Project Oncology®
Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
MinuteCE®
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025  
0.50 credits 3 episodes
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 credits 3 episodes
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Project Oncology®
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
- Charles Turck, PharmD, BCPS, BCCCP
- Jonathon B. Cohen, MD, MS
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Project Oncology®
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
- Charles Turck, PharmD, BCPS, BCCCP
- Jonathon B. Cohen, MD, MS
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Project Oncology®
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
- Hallie Blevins, PhD.
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
Global Oncology Academy
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
- Gerard A. Silvestri MD, MS, Master FCCP
- Jessica S. Donington, MD, MSCR
- Mariam Alexander, MD, PhD
- Anurag Singh, MD
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
Global Oncology Academy
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
- Gerard A. Silvestri MD, MS, Master FCCP
- Jessica S. Donington, MD, MSCR
- Mariam Alexander, MD, PhD
- Anurag Singh, MD

Medical News

Medical News
Mitochondrial Gene Signatures Linked to Heart Damage in Childhood Cancer Survivors
10/07/2025
Read more
Medical News
New Meta-Analysis Strengthens Link Between Severe Sunburn and Skin Cancer Risk
10/06/2025
Read more
Medical News
Lung Cancer Treatment: Evaluating Surgery, Radiation, and Novel Therapies
10/01/2025
Read more
Medical News
HIV-Related Lymphomas and the COVID-19 Pandemic
09/30/2025
Read more

See more news

CME/CE

Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
MinuteCE®
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
0.50 program credits
- Lauren A. Byers, MD
0.50 program credits
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
MinuteCE®
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
MinuteCE®
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
MinuteCE®
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits

Clinical Practice

Managing Chronic Graft-Versus-Host Disease with CSF1R Inhibition
Managing Chronic Graft-Versus-Host Disease with CSF1R Inhibition
Project Oncology®
Managing Chronic Graft-Versus-Host Disease with CSF1R Inhibition
- Jennifer Caudle, DO
- Andrew Harris, MD
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Project Oncology®
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
- Ryan Quigley
Elacestrant and Targeted Therapies in Breast Cancer: Preliminary Data From ELECTRA and ELEVATE
Elacestrant and Targeted Therapies in Breast Cancer: Preliminary Data From ELECTRA and ELEVATE
Project Oncology®
Elacestrant and Targeted Therapies in Breast Cancer: Preliminary Data From ELECTRA and ELEVATE
- Jennifer Caudle, DO
- Hope S. Rugo, MD, FASCO
Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers
Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers
Project Oncology®
Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers
- Paola Marignani, PhD, EMBA

Programs

Exploring Elacestrant Combinations for ER+/HER2- mBC: Early Data from ELEVATE
Exploring Elacestrant Combinations for ER+/HER2- mBC: Early Data from ELEVATE
Project Oncology®
Exploring Elacestrant Combinations for ER+/HER2- mBC: Early Data from ELEVATE
- Charles Turck, PharmD, BCPS, BCCCP
- Virginia Kaklamani, MD
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
Project Oncology®
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
- Charles Turck, PharmD, BCPS, BCCCP
- Sairah Ahmed, MD
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
Project Oncology®
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
- Charles Turck, PharmD, BCPS, BCCCP
- Samuel Yamshon, MD
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
Project Oncology®
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
- Charles Turck, PharmD, BCPS, BCCCP
- Samuel Yamshon, MD